Marché clinique des tests de mycoplasmes en Asie-Pacifique – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des tests de mycoplasmes en clinique en Asie-Pacifique

Le CDC prévoit que 152 657 personnes sont décédées en 2021 des suites de maladies chroniques des voies respiratoires inférieures. Le marché des tests de mycoplasmes en milieu clinique est en pleine expansion en raison du nombre croissant de décès dus aux maladies respiratoires, aux maladies pulmonaires et à la tuberculose, et ces chiffres devraient continuer à augmenter dans les années à venir. Actuellement, les laboratoires cliniques et de santé publique utilisent fréquemment des techniques de tests moléculaires. La Food and Drug Administration (FDA) des États-Unis a approuvé un certain nombre de kits de tests moléculaires disponibles dans le commerce pour identifier M. pneumoniae. La majorité de ces kits sont utilisés pour la détection de M. pneumoniae ainsi que d'autres infections respiratoires. Les laboratoires de santé publique locaux ou nationaux peuvent offrir une aide au diagnostic ou envoyer des échantillons au CDC lorsque des tests supplémentaires ou spécialisés sont nécessaires.

Français Data Bridge Market Research analyse que le marché des tests de mycoplasmes sur le marché clinique, qui était de 52,52 millions USD en 2022, devrait atteindre 98,66 millions USD d'ici 2030, à un TCAC de 8,2 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché clinique des tests de mycoplasmes en Asie-Pacifique  

Market Definition

Mycoplasma is a form of bacterial infection that can be found by using a mycoplasma test. There are various mycoplasma infections, testing can be carried out in a number of methods depending on which one is suspected. M. pneumoniae, which causes upper respiratory infections and can be detected with a blood sample, is mycoplasma's most prevalent. A vaginal swab, joint fluid, bodily fluids, tissue samples and other sample types may need to be collected for further mycoplasma testing such as sputum.

Asia-Pacific Mycoplasma Testing in Clinical Market Dynamics

Drivers

• Growing R&D investments

The adoption of highly effective mycoplasma testing technologies will certainly be encouraged by rising research expenditures and rising R&D investments by major corporations. For instance, Bristol-Myers Squibb started spending money on creating experimental drugs to help clinical trials. Furthermore, it is essential to carry out safety testing to make sure that a product meets the requirements for efficacy, safety and general public health. This is because of the emergence of biosimilars and the lucrative R&D investment that followed. In December 2020, Merck KGaA increased the size of its American manufacturing footprint by investing more than USD 45.6 million (EUR 40 million) in its Massachusetts and New Hampshire production sites. The facilities were created to increase the company's capability for production while producing a range of biopharmaceutical manufacturing products. These are the factors which further propel the market growth.

• Growing concerns over cell culture contamination

Contamination is the most frequent issue in cell culture laboratories. Chemical and biological contamination are the two categories into which cell culture contaminations are divided. Serum, water, endotoxins and impurities are a few instances of chemical pollutants. Testing for mycoplasma is one of the procedures used to find contamination.

Opportunities

• Globalization of clinical trials

ELISA technology is predicted to achieve a sizable market share throughout the forecast period because it allows for simple detection using labeled probes or antibodies for mycoplasma detection. In some cases, PCR and ELISA tests are combined to create PCR-ELISA, a photometric enzyme-based immunoassay that makes it easier to find mycoplasma DNA that PCRPCR has amplified has amplified in samples. The segment growth will be fuelled by factors such as functional advantages, cost effectiveness, and the capacity to identify a wide variety of strains during the forecast period.

Restraints/Challenges

• High cost of instruments

The mycoplasma testing in clinical market expansion is anticipated to be restrained by the high cost of equipment and the time-consuming and tedious detection method, during the forecast period. One of the most frequent causes of both paediatric and adult community-acquired pneumonia is Mycoplasma pneumoniae.

This mycoplasma testing in clinical market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mycoplasma testing in clinical market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Liofilchem S.r.l. Introduced the enhanced AF Genital System, VTM, Lockable contact plates with microbiological testing. The company's revenue increased because to this product upgrade.

• In 2020, BioMérieux SA announced the introduction of the biofire mycoplasma test for the detection of mycoplasma in biopharmaceutical products. This strategy helped the business increase the market shares of its product in the biotherapeutics sector.

COVID-19 Impact on the Mycoplasma Testing in Clinical Market

The COVID-19 outbreak has had a detrimental impact on all sectors of the economy and is still having a negative effect. When compared to other industries, the biopharmaceutical industry and adjacent markets have not been considerably affected. A study released in May 2022 found a connection between the quantity of mycoplasma tests and COVID-19-related non-pharmaceutical interventions (NPIs). The incidence of M. pneumonia following the adoption of COVID-19 NPIs was examined in this study. This study revealed a decline in M. pneumoniae detection throughout the epidemic. This decrease was noticed between March 2020 and March 2021. This decrease is mostly attributable to the limited spread of M. pneumonia, which has led to a sharp decline in M. pneumoniae infections worldwide.

Asia-Pacific Mycoplasma Testing in Clinical Market Scope

The mycoplasma testing in clinical market is segmented on the basis of products, technique, application, disease area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Kits and Reagents
• PCR Assays
• Nucleic Acid Detection Kits
• Stains
• Elimination Kits
• Standards and Controls
• Others
• Instruments
• Services

 Technique

• Microbial Culture Techniques/Direct Assay
• Polymerase Chain Reaction
• ELISA
• DNA Staining/Indirect Assay
• Enzymatic Methods

 Application

• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others

 Disease Area

• Respiratory
• Urogenital
• Gastrointestinal
• Musculoskeletal
• Cardiovascular
• Others

 End User

• Diagnostic Laboratories
• Hospitals

Mycoplasma Testing in Clinical Market Regional Analysis/Insights

The mycoplasma testing in clinical market is analyzed and market size insights and trends are provided by country, products, technique, application disease area and end user as referenced above.

The countries covered in the mycoplasma testing in clinical market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

Japan is leading the growth in the market due to rise in healthcare expenditure, growing research activities conducted by pharmaceutical and biotechnology companies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The mycoplasma testing in clinical market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for mycoplasma testing in clinical market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the mycoplasma testing in clinical market. The data is available for historic period 2011-2021.

Competitive Landscape and Mycoplasma Testing in Clinical Market Share Analysis

Le paysage concurrentiel du marché des tests de mycoplasmes sur le marché clinique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées aux tests de mycoplasmes sur le marché clinique.

Certains des principaux acteurs opérant sur le marché des tests de mycoplasmes sur le marché clinique sont :

• AB ANALITICA srl (Italie)
• BIOMÉRIEUX (France)
• Groupe ELITech (France)
• Liofilchem ​​Srl (Italie)
• Agilent Technologies, Inc. (États-Unis)
• PromoCell GmbH (Allemagne)
• F. Hoffmann-La Roche SA (Suisse)
• OSANG Healthcare (Corée du Sud)
• Sacace Biotechnologies Srl (Italie)
• Lonza (Suisse)
• Merck KGaA (Allemagne)
• Seegene Inc. (Corée du Sud)
• Clongen Laboratories, LLC (États-Unis)
• Bio-Rad Laboratories, Inc. (États-Unis)
• Charles River Laboratories (États-Unis)
• Bionique Testing Laboratories LLC (États-Unis)
• Diagnostic ZEAKON (Inde) 

SKU-44727